SUZHOU, China, December 30, 2021 — Dr. Jinzhong Zhang, Co-founder, Chairman and CEO of Eluminex Biosciences (Suzhou) Limited (Eluminex) was invited as a guest speaker at the DeviceChina 2021, held by BioBAY, Suzhou Industrial Park, on October 24, 2021, where Dr. Zhang gave a presentation on the recent progress on biologics drug development in retinal diseases. On November 17, 2021, Dr. Zhang was invited as a panelist to the China Healthcare Summit, which was jointly organized by BioCentury and BayHelix. At this Summit, Dr. Zhang shared the Eluminex vision as an innovation-driven ophthalmic biotech company and his views on opportunities and challenges of China biomedical industry.
Dr. Jinzhong Zhang received his PhD in Molecular Biology through a joint program between Peking University and Kyoto University and served as an Assistant Professor of Ophthalmology at Case Western Reserve University. He served as Principal Investigators on 5 research projects of diabetic retinopathy awarded by the National Eye Institute of the National Institutes of Health (NIH) and the American Diabetes Association (ADA). With 25 years in ophthalmic research and drug development in the United States and Japan, Dr. Zhang has held senior leadership roles in both private (Graybug Vision; Nasdaq: GRAY) and large global ophthalmology companies (Santen Pharmaceutical and Bausch + Lomb) and led in the research and development of several marketed products.
About Eluminex Biosciences
Eluminex Biosciences (Eluminex) is a privately held clinical-stage biotechnology company focused on both global and regional development and commercialization of innovative therapeutics to fulfill unmet medical needs in the treatment and management of ophthalmic diseases. Eluminex is devoted towards innovating the next generation of first-in-class or best-in-class ocular therapeutics for vision-threatening or lifestyle-limiting ocular diseases. Eluminex has developed a pipeline of multivalent next generation protein therapeutics for retinal diseases (EB-101, EB-102, EB-105, and EB-107) including age-related macular degeneration, macular edema, and diabetic retinopathy; these assets are wholly owned and developed by Eluminex. In addition, Eluminex is currently developing the world’s first recombinant human collagen-derived biosynthetic cornea (EB-301) for the treatment of corneal blindness.
The Eluminex global headquarters and research and development center are in Suzhou BioBAY Industrial Park, China with a US-subsidiary located in the San Francisco Bay Area. Eluminex is supported by three premiere global life science venture funds: Lilly Asia Ventures, Hillhouse Capital Management, and Quan Capital.
For more information, please visit www.eluminexbio.com.
Contact for Investors/Media:
Zhenze John Hu, PhD, MPD